Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2020: (Do not round intermediate calculations. Round final answers to nearest whole dollar.)

Asset	Date of Purchase	Deprec. Method*	Cost			Residual Value			Useful Life	Accum. Deprec.			Recoverable Amount
Equipment	May 1/15	Units	$	60,000		$	4,750		8,500 units	$	35,750		$	7,750
Furniture	Jun. 28/15	DDB		27,000			3,500		8 yrs		22,559			5,050
Land	Apr. 5/15	N/A		100,000			N/A		N/A		N/A			116,800
Office building	Apr. 5/15	SL		107,000			30,500		15 yrs		36,500			67,500
Warehouse	Apr. 5/15	SL		77,500			25,000		20 yrs		27,938			60,100

*DDB = Double-declining-balance; SL = Straight-line; Units = Units-of-production; N/A = Not applicable Required: 1. Record any impairment losses at December 31, 2020. Assume Kane Biotech has recorded no impairment losses in previous years.

2. Record depreciation for each asset at December 31, 2021. Assume that there was no change in the residual values or useful lives regardless of any impairment losses that might have occurred. The equipment produced 2,550 units during 2021.